These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 27391466)

  • 1. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
    Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
    Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.
    Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ
    Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
    Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
    Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
    Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
    Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer.
    Shapiro M; Chen Q; Huang Q; Boosalis VA; Yoon CH; Saund MS; Whang EE; Gold JS
    JAMA Surg; 2016 Apr; 151(4):338-45. PubMed ID: 26581025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.
    Lim JE; Chien MW; Earle CC
    Ann Surg; 2003 Jan; 237(1):74-85. PubMed ID: 12496533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
    Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
    World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Different Treatment Modalities on the Outcome of Pancreatic Cancer.
    Khan M; Ashraf MI; Syed AA; Hanif F
    J Coll Physicians Surg Pak; 2017 Aug; 27(8):470-474. PubMed ID: 28903837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
    de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
    Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
    Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
    HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base.
    Kooby DA; Gillespie TW; Liu Y; Byrd-Sellers J; Landry J; Bian J; Lipscomb J
    Ann Surg Oncol; 2013 Oct; 20(11):3634-42. PubMed ID: 23771249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.